{"nctId":"NCT00122460","briefTitle":"Cetuximab (Erbitux) in Combination With Cisplatin or Carboplatin and 5-Fluorouracil in the First Line Treatment of Subjects With Recurrent and/or Metastatic Squamous Cell Carcinoma of the Head and Neck (EXTREME)","startDateStruct":{"date":"2004-12"},"conditions":["Head and Neck Cancer"],"count":442,"armGroups":[{"label":"Cetuximab Plus Chemotherapy","type":"EXPERIMENTAL","interventionNames":["Drug: Cetuximab + Platinum (Cisplatin or Carboplatin) + 5Fluorouracil (5-FU)"]},{"label":"Chemotherapy alone","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: Platinum (Cisplatin or Carboplatin) + 5-FU"]}],"interventions":[{"name":"Cetuximab + Platinum (Cisplatin or Carboplatin) + 5Fluorouracil (5-FU)","otherNames":[]},{"name":"Platinum (Cisplatin or Carboplatin) + 5-FU","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Histologically or cytologically confirmed diagnosis of squamous cell carcinoma of the head and neck (SCCHN)\n* Recurrent and/or metastatic SCCHN, not suitable for local therapy\n\nExclusion Criteria:\n\n* Prior systemic chemotherapy, except if given as part of a multimodal treatment for locally advanced disease which was completed more than 6 months prior to study entry\n* Surgery (excluding prior diagnostic biopsy), or irradiation within 4 weeks before study entry\n* Nasopharyngeal carcinoma","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Overall Survival Time (OS)","description":"Time from randomization to death. Patients without event are censored at the last date known to be alive or at the clinical cut-off date, whatever is earlier.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"10.1","spread":null},{"groupId":"OG001","value":"7.4","spread":null}]}]}]},{"type":"SECONDARY","title":"Progression-free Survival Time (PFS)","description":"Duration from randomization until radiological progression according to investigator (based on modified World Health Organisation (WHO) criteria) or death due to any cause.\n\nOnly deaths within 60 days of last tumor assessment are considered. Patients without event are censored on the date of last tumor assessment.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"5.6","spread":null},{"groupId":"OG001","value":"3.3","spread":null}]}]}]},{"type":"SECONDARY","title":"Best Overall Response","description":"The best overall response rate is defined as the percentage of subjects having achieved confirmed Complete Response + Partial Response as the best overall response according to radiological assessments according to investigator (based on modified WHO criteria).","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"35.6","spread":null},{"groupId":"OG001","value":"19.5","spread":null}]}]}]},{"type":"SECONDARY","title":"Disease Control","description":"The disease control rate is defined as the percentage of subjects having achieved confirmed Complete Response + Partial Response + Stable Disease as best overall response according to radiological assessments according to investigator (based on modified WHO criteria).","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"81.1","spread":null},{"groupId":"OG001","value":"60.0","spread":null}]}]}]},{"type":"SECONDARY","title":"Time to Treatment Failure","description":"Time from randomization to date of the first occurrence of; progression, discontinuation of treatment due to progression or adverse event, start of new anticancer therapy, withdrawal of consent, or death (within 60 days of last tumor assessment).\n\nPatients without event are censored on the date of last tumor assessment.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"4.8","spread":null},{"groupId":"OG001","value":"3.0","spread":null}]}]}]},{"type":"SECONDARY","title":"Duration of Response","description":"Time from first assessment of Complete Response or Partial Response to disease progression or death (within 60 days of last tumor assessment).\n\nPatients without event are censored on the date of last tumor assessment. Tumor assessments based on modified WHO criteria.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"5.6","spread":null},{"groupId":"OG001","value":"4.7","spread":null}]}]}]},{"type":"SECONDARY","title":"Quality of Life (QOL) Assessment European Organisation for the Research and Treatment of Cancer (EORTC) QLQ-C30 Global Health Status","description":"Mean global health status scores (EORTC QLQ-C30) against time for each treatment group. Scores were derived from mutually exclusive sets of items, with scale scores ranging from 0 to 100 after a linear transformation. Higher scores indicate a better QoL.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"50.74","spread":"3.519"},{"groupId":"OG001","value":"45.15","spread":"3.745"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"52.68","spread":"3.724"},{"groupId":"OG001","value":"45.48","spread":"4.153"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"55.30","spread":"4.282"},{"groupId":"OG001","value":"42.49","spread":"5.959"}]}]}]},{"type":"SECONDARY","title":"Quality of Life Assessment (EORTC QLQ-C30) Social Functioning","description":"Mean social functioning scores (EORTC QLQ-C30) against time for each treatment group. Scores were derived from mutually exclusive sets of items, with scale scores ranging from 0 to 100 after a linear transformation. Higher scores indicate a higher level of social functioning.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"62.14","spread":"4.459"},{"groupId":"OG001","value":"62.05","spread":"4.730"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"64.64","spread":"4.663"},{"groupId":"OG001","value":"60.67","spread":"5.176"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"61.27","spread":"5.347"},{"groupId":"OG001","value":"65.72","spread":"7.122"}]}]}]},{"type":"SECONDARY","title":"Safety - Number of Patients Experiencing Any Adverse Event","description":"Please refer to Adverse Events section for further details","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"218","spread":null},{"groupId":"OG001","value":"208","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":110,"n":219},"commonTop":["Nausea","Anaemia","Vomiting","Neutropenia","Asthenia"]}}}